Table 2.
Measured vitamins (25-OH-vitamin D, pyridoxic acid),lipids (7 LPC, 1 LPE, 10 PC), malonylcarnitine, plasma organic acids (inositol, pyroglutamic acid, methylmalonic acid), urine organic acids (uracil, succinic acid, citric acid) and linolenylethanolamide are listed for all significant phase comparison categories.
| Biomarkers vs. Phase contrasts | Effect Size** | FDR q values*** | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| L-F* | L-M | L-O | P-L | O-M | q L-F | q L-M | q L-O | q P-L | q O-M | |
| Vitamins | ||||||||||
| 25-OH-vitamin-D - serum (nmol/L) | −0.06 | −0.09 | 0.01 | 0.00 | −0.10 | 4.82E-01 | 1.21E-02 | 3.85E-02 | ||
| Pyridoxic acid - plasma (nmol/L) | 0.05 | −0.16 | 0.29 | 0.18 | −0.45 | 1.18E-01 | ||||
| Lipids, plasma | ||||||||||
| LPC 18:2 | −0.26 | −0.17 | −0.08 | 0.22 | −0.09 | 4.78E-04 | 2.89E-01 | |||
| LPC 22:6 | −0.20 | −0.18 | −0.09 | 0.17 | −0.09 | 1.76E-02 | 2.89E-01 | |||
| LPE 22:6 | −0.34 | −0.27 | −0.21 | 0.27 | −0.06 | 1.45E-02 | 2.89E-01 | |||
| PC O-42:6 | −0.13 | −0.09 | −0.06 | 0.10 | −0.03 | 1.11E-02 | 9.34E-01 | |||
| PC 40:8 | −0.15 | −0.07 | −0.01 | 0.09 | −0.06 | 2.41E-03 | ||||
| LPC 18:3 | −0.30 | −0.09 | 0.02 | 0.26 | −0.11 | 1.76E-02 | ||||
| PC O-34:3 | −0.14 | −0.02 | −0.09 | 0.09 | 0.08 | 2.64E-02 | ||||
| LPC 16:1 | −0.20 | −0.11 | −0.02 | 0.05 | −0.08 | 1.76E-02 | ||||
| PC 34:3 | −0.19 | −0.02 | −0.04 | 0.10 | 0.02 | 3.30E-02 | ||||
| LPC 20:3 | −0.16 | −0.07 | 0.02 | 0.07 | −0.10 | 3.83E-02 | ||||
| LPC 20:4 | −0.17 | −0.12 | −0.06 | 0.12 | −0.06 | 1.76E-02 | ||||
| PC O-38:7 | −0.09 | −0.02 | −0.04 | 0.11 | 0.02 | 7.74E-02 | ||||
| PC 34:2 | −0.08 | −0.02 | −0.06 | 0.02 | 0.03 | 3.30E-02 | ||||
| PC 32:2 | −0.26 | −0.19 | −0.05 | 0.17 | −0.14 | 3.30E-02 | ||||
| PC 36:2 | −0.09 | −0.02 | −0.02 | 0.03 | 0.00 | 9.41E-02 | ||||
| PC 36:4 | −0.08 | −0.01 | −0.04 | 0.03 | 0.02 | 1.26E-01 | ||||
| PC O-36:5 | −0.13 | −0.03 | −0.07 | 0.10 | 0.04 | 1.26E-01 | ||||
| LPC 18:0 | −0.11 | −0.11 | 0.08 | 0.03 | −0.19 | 4.78E-01 | 1.60E-01 | |||
| Acylcarnitines, urine | ||||||||||
| Malonylcarnitine | −0.18 | 0.18 | −0.43 | 0.19 | 0.61 | 1.96E-01 | ||||
| Organic Acids, plasma | ||||||||||
| Inositol | −0.20 | −0.30 | −0.40 | 0.30 | 0.10 | 9.53E-02 | 9.62E-02 | 1 | 1 | |
| Pyroglutamic acid | −0.14 | −0.39 | −0.46 | 0.23 | 0.07 | 2.11E-02 | 9.62E-02 | |||
| Methylmalonic acid | −0.12 | −0.18 | −0.13 | 0.06 | −0.04 | 9.53E-02 | ||||
| Organic Acids, urine | ||||||||||
| Uracil | 0.27 | 0.39 | −0.23 | −0.28 | 0.61 | 4.11E-01 | 3.74E-02 | |||
| Succinic acid | −0.03 | 0.26 | −0.30 | 0.07 | 0.57 | 9.67E-02 | ||||
| Citric acid | 0.00 | 0.17 | −0.16 | −0.03 | 0.33 | 1.80E-01 | ||||
| Endocannabinoids, plasma | ||||||||||
| Linolenoylethanolamide (LEA) | −0.15 | −0.08 | −0.11 | 0.02 | 0.03 | 1.92E-02 | ||||
*Luteal/follicular (L-F), luteal-menstrual (L-M), luteal-periovulatory (L-O), premenstrual-luteal (P-L) and peri-ovular-menstrual (O-M); **All results are based on natural log transformed data. Effect sizes are estimated phase-phase differences (“contrasts”). ***Student’s t-test p-values of the contrasts are controlled for multiple testing within metabolites by Bonferroni and across metabolites using Benjamini-Hochberg FDR, resulting in q values as listed. Significant q values are in bold.Values above 0.50 are intentionally left blank. LPC, Lysophosphatidylcholine, LPE- Lysophosphatidylethanolamine, PC-phosphatidylcholine.